Lots of follow up exciting immunology to come! Thanks to three big teams combined effort Bridget Barber and Chris Engwerda @qimrb.bsky.social and our team, now @burnetinstitute.bsky.social, plus Stanford HIMC and Gates Foundation Global Health Discovery Collaboratory, @mmv.org and others.

Type I IFN response to malaria, and excessive signalling induces Type I regulatory CD4 T cells. We tested whether targeting this signalling with a JAK inhibitor ruxolitinib could be a host directed therapy to boost immunity. Exciting results show reduced inflammation and evidence of increased memory